Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis

Remission induction in antineutrophil cytoplasmic autoantibody (ANCA) vasculitis may be complicated by slow response to treatment and toxicity from glucocorticoids. We describe outcomes with a novel remission induction regimen combining rituximab with a short course of low-dose, oral cyclophosphamid...

Full description

Bibliographic Details
Main Authors:	Frank B. Cortazar, Saif A. Muhsin, William F. Pendergraft, III, Zachary S. Wallace, Colleen Dunbar, Karen Laliberte, John L. Niles
Format:	Article
Language:	English
Published:	Elsevier 2018-03-01
Series:	Kidney International Reports
Subjects:	ANCA vasculitis cyclophosphamide remission rituximab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024917304394

Similar Items

Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly
by: Roberta Fenoglio, et al.
Published: (2020-10-01)

Adding low dose cyclophosphamide to rituximab for remission-induction may prolong relapse-free survival in patients with ANCA vasculitis: A retrospective study
by: Renée Ysermans, et al.
Published: (2023-01-01)

Hypophysitis Secondary to Small Vessel ANCA Vasculitis Treated With Rituximab
by: Nankee K. Kumar, AB, et al.
Published: (2024-03-01)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
by: Elena Treppo, et al.
Published: (2021-08-01)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
by: Mark E. McClure, et al.
Published: (2023-03-01)

Favorable efficacy of rituximab in ANCA-associated vasculitis patients with excessive B cell differentiation
by: Yusuke Miyazaki, et al.
Published: (2020-06-01)

Serum B cell activating factor (BAFF) as a biomarker for induction of remission with rituximab in ANCA-associated vasculitis
by: Kazuyuki Tsuboi, et al.
Published: (2022-10-01)

ANCA-associated vasculitis in a 14 years-old patient: a clinical case
by: A. V. Burlutskaya, et al.
Published: (2020-10-01)

A Personalized Rituximab Retreatment Approach Based on Clinical and B-Cell Biomarkers in ANCA-Associated Vasculitis
by: Jack Arnold, et al.
Published: (2022-01-01)

Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report
by: O. Psenak, et al.
Published: (2021-08-01)

Rituximab Therapy for Severe Cutaneous Leukocytoclastic Angiitis Refractory to Corticosteroids, Cellcept and Cyclophosphamide
by: Kamel El-Reshaid, et al.
Published: (2013-04-01)

Covid-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2020-09-01)

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis
by: Anji Xiong, et al.
Published: (2021-03-01)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
by: L. Caroti, et al.
Published: (2019-05-01)

COVID-19 in a patient with ANCA-associated systemic vasculitis, receiving anti-B cell therapy (rituximab)
by: T. V. Beketova, et al.
Published: (2018-06-01)

Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
by: Michael S. Sagmeister, et al.
Published: (2018-10-01)

Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report
by: Claire Harris, et al.
Published: (2018-06-01)

Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis
by: Gwen E. Thompson, et al.
Published: (2020-09-01)

ANCA‐associated vasculitis with scleritis, corneal melt, and perforation rescued by rituximab: Case report and literature review
by: Toshihiko Matsuo, et al.
Published: (2023-06-01)

ANCA-Associated Vasculitis: An Update
by: Salem Almaani, et al.
Published: (2021-04-01)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
by: Ana Teresa Domingos, et al.
Published: (2019-10-01)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
by: Laura S. van Dam, et al.
Published: (2020-12-01)

Treating Patients With ANCA-Associated Vasculitis and Very Severe Renal Injury With an Intensified B Cell Depletion Therapy: Comparison With a Control Cohort Receiving a Conventional Therapy
by: Dario Roccatello, et al.
Published: (2022-03-01)

Incidence of serious infections in patients with ANCA-associated vasculitis receiving immunosuppressive therapy: A systematic review and meta-analysis
by: Athanasios Vassilopoulos, et al.
Published: (2023-03-01)

Methimazole-Induced ANCA Vasculitis: A Case Report
by: Precil Diego Miranda de Menezes Neves, et al.
Published: (2021-08-01)

Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study
by: Dimitrios Chanouzas, et al.
Published: (2019-02-01)

Environmental factors influencing the risk of ANCA-associated vasculitis
by: Wen-Man Zhao, et al.
Published: (2022-09-01)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
by: Zachary S. Wallace, et al.
Published: (2019-12-01)

Complement Inhibition in ANCA-Associated Vasculitis
by: Vladimir Tesar, et al.
Published: (2022-07-01)

Cyclophosphamide Versus Rituximab in Progressive Forms of Multiple Sclerosis
by: Masoud Etemadifar, et al.
Published: (2020-02-01)

The neutrophil-to-lymphocyte ratio as a marker of vasculitis activity, severe infection and mortality in anca-associated vasculitis: A retrospective study
by: José Agapito Fonseca, et al.
Published: (2021-05-01)

ANCA-ASSOCIATED VASCULITIS: HETEROGENEITY OF CLINICAL MANIFESTATIONS, PROGNOSIS, CURRENT OPPORTUNITIES OF PHARMACOTHERAPY
by: O.B. Yaremenko, et al.
Published: (2017-11-01)

Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review
by: Andreea Covic, et al.
Published: (2023-10-01)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
by: Mohammad Amin Habibi, et al.
Published: (2022-12-01)

Otologic manifestations in the setting of seronegative small vessel vasculitis: A case report
by: Kathleen Gillmore, et al.
Published: (2023-06-01)

GENETIC SUSCEPTIBILITY TO ANCA-ASSOCIATED VASCULITIS: STATE OF THE ART
by: Francesco eBonatti, et al.
Published: (2014-11-01)

Compromiso del sistema nervioso en vasculitis asociadas a ANCA
by: María Fernanda Quaglia
Published: (2018-06-01)

MPO-ANCA-associated necrotizing glomerulonephritis in rheumatoid arthritis; a case report and review of literature
by: Mário Góis, et al.
Published: (2017-04-01)

The Role of Neutrophils in ANCA-Associated Vasculitis: The Pathogenic Role and Diagnostic Utility of Autoantibodies
by: Agata Walulik, et al.
Published: (2023-12-01)

Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
by: Shah S, et al.
Published: (2015-08-01)